Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
Phase 1
Completed
NCT05711381
| Condition | Renal Impairment |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
|---|
| Status | Completed |
|---|
| Enrollment | 16 participants |
|---|
| Interventions | HM15912 |
|---|
| Start date | Dec 2, 2022 |
|---|
| Completion date | Aug 15, 2023 |
|---|
| Results posted | Apr 4, 2025 |
|---|
Summary
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HM15912 in Subjects with Renal Impairment and Matched Control Subjects with Normal Renal Function
Maximum Serum Concentration (Cmax) of HM15912
Day 1 to 29 (Total duration: 29 days) · ng/mL
| Severe Renal Impairment | 2811.25 ± 1498.985 ng/mL |
|---|
| Normal Renal Function | 3000.00 ± 1174.114 ng/mL |
|---|
| Geometric mean ratio | 0.91 (95% CI 0.59–1.41) |
|---|
Area Under the Concentration-time Curve From Extrapolated to Infinity (AUC 0-infinity) of HM15912
Day 1 to 29 (Total duration: 29 days) · h*ng/mL
| Severe Renal Impairment | 1117469.3 ± 347572.67 h*ng/mL |
|---|
| Normal Renal Function | 890343.8 ± 235565.36 h*ng/mL |
|---|
| Geometric mean ratio | 1.25 (95% CI 0.93–1.68) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.